# JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

Source: https://onco.cc/trials/nct04892173/  
OnCo record `nct04892173` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing JNJ-90301900 in head and neck squamous cell carcinoma, now recruiting.

## Summary

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC is a phase 3 interventional study registered as NCT04892173, led by Johnson & Johnson Enterprise Innovation, and recruiting on the registry. Official title: A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With Locally Advanced Head & Neck Squamous Cell Carcinoma. Planned enrolment is 500 participants (estimated). The study started in 2021-12-10 and primary completion is expected in 2028-06-30. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT04892173
- Phase: 3
- Setting: A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With Locally Advanced Head & Neck Squamous Cell Carcinoma
- Sponsor: Johnson & Johnson Enterprise Innovation
- Enrolled: 500

## Sources

- ClinicalTrials.gov NCT04892173: https://clinicaltrials.gov/study/NCT04892173

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- drugs: [JNJ-90301900](https://onco.cc/drugs/jnj-90301900/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)

---
JSON: https://onco.cc/api/v1/entities/nct04892173.json